These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31359797)

  • 21. Tau protein, beta-amyloid₁₋₄₂ and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia.
    Vranová HP; Hényková E; Kaiserová M; Menšíková K; Vaštík M; Mareš J; Hluštík P; Zapletalová J; Strnad M; Stejskal D; Kaňovský P
    J Neurol Sci; 2014 Aug; 343(1-2):120-4. PubMed ID: 24928081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
    Williams SM; Schulz P; Sierks MR
    Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.
    Eidson LN; Kannarkat GT; Barnum CJ; Chang J; Chung J; Caspell-Garcia C; Taylor P; Mollenhauer B; Schlossmacher MG; Ereshefsky L; Yen M; Kopil C; Frasier M; Marek K; Hertzberg VS; Tansey MG
    J Neuroinflammation; 2017 Aug; 14(1):164. PubMed ID: 28821274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.
    Li X; Fan X; Yang H; Liu Y
    Mol Neurobiol; 2022 Feb; 59(2):1041-1057. PubMed ID: 34826053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cerebrospinal fluid alpha-synuclein as a biomarker for Parkinson's disease diagnosis: a systematic review and meta-analysis.
    Gao L; Tang H; Nie K; Wang L; Zhao J; Gan R; Huang J; Zhu R; Feng S; Duan Z; Zhang Y; Wang L
    Int J Neurosci; 2015; 125(9):645-54. PubMed ID: 25202803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
    Jellinger KA
    Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
    Johar I; Mollenhauer B; Aarsland D
    Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.
    Teixeira Dos Santos MC; Bell R; da Costa AN
    Bioanalysis; 2016 Dec; 8(23):2497-2518. PubMed ID: 27855513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers of Parkinson's disease and Dementia with Lewy bodies.
    Henchcliffe C; Dodel R; Beal MF
    Prog Neurobiol; 2011 Dec; 95(4):601-13. PubMed ID: 21983334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Concept of Prodromal Parkinson's Disease.
    Mahlknecht P; Seppi K; Poewe W
    J Parkinsons Dis; 2015; 5(4):681-97. PubMed ID: 26485429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery, validation and optimization of cerebrospinal fluid biomarkers for use in Parkinson's disease.
    Farotti L; Paciotti S; Tasegian A; Eusebi P; Parnetti L
    Expert Rev Mol Diagn; 2017 Aug; 17(8):771-780. PubMed ID: 28604235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apolipoprotein E4 serum concentration for increased sensitivity and specificity of diagnosis of drug treated Alzheimer's disease patients vs. drug treated parkinson's disease patients vs. age-matched normal controls.
    Goldknopf IL; Park HR; Sabbagh M
    Curr Alzheimer Res; 2012 Dec; 9(10):1149-67. PubMed ID: 22950864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases.
    Hölscher C
    Biochem Soc Trans; 2014 Apr; 42(2):593-9. PubMed ID: 24646283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosensor approaches on the diagnosis of neurodegenerative diseases: Sensing the past to the future.
    Karaboğa MNS; Sezgintürk MK
    J Pharm Biomed Anal; 2022 Feb; 209():114479. PubMed ID: 34861607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic utility of quantitating neurofilament-immunoreactive Alzheimer's disease lesions.
    de la Monte SM; Wands JR
    J Histochem Cytochem; 1994 Dec; 42(12):1625-34. PubMed ID: 7983363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive and behavioral assessment in Parkinson's disease.
    Martinez-Horta S; Horta-Barba A; Kulisevsky J
    Expert Rev Neurother; 2019 Jul; 19(7):613-622. PubMed ID: 31180250
    [No Abstract]   [Full Text] [Related]  

  • 38. Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research.
    Khan MA; Haider N; Singh T; Bandopadhyay R; Ghoneim MM; Alshehri S; Taha M; Ahmad J; Mishra A
    Metab Brain Dis; 2023 Mar; 38(3):873-919. PubMed ID: 36807081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes Mellitus and Energy Dysmetabolism in Alzheimer's Disease: Understanding the Relationships and Potential Therapeutic Targets.
    Onaolapo AY; Ojo FO; Adeleye OO; Falade J; Onaolapo OJ
    Curr Diabetes Rev; 2023; 19(8):e020123212333. PubMed ID: 36593701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Parkinson's and Alzheimer's diseases: Focus on mild cognitive impairment.
    Korczyn AD
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1():S159-61. PubMed ID: 26516060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.